Effectiveness of netarsudil 0.02% in lowering intraocular pressure in patients with secondary glaucoma

by Selleckchem | Oct 01 2023

Objective: To determine the effectiveness of netarsudil, 0.02% in lowering intraocular pressure (IOP) in patients with secondary forms of glaucoma.

Methods: A total of 77 patients (98 eyes) with either primary open-angle glaucoma (POAG) or secondary glaucoma were reviewed retrospectively over the course of 1 year after starting netarsudil. The secondary glaucoma group was comprised of patients with uveitic, pseudoexfoliative, neovascular, congenital, and other forms of secondary glaucoma. Patient IOP measurements were collected at baseline and at 1-, 3-, 6-, and 12-month intervals. Two sample t tests and 1-way analysis of variance were used to determine differences in IOP reductions following netarsudil treatment.

Results: Patients with POAG or secondary glaucomas were matched for age (mean ± SD: 69.1 ± 16.0 years vs. 64.5 ± 21.2 years; p = 0.30). Both the POAG and secondary glaucoma patients exhibited significant decreases in IOP at each time point (1, 3, 6, and 12 months) when compared with baseline (p < 0.05). Both groups showed similar overall decreases in IOP from baseline after 1 year of treatment (6.0 ± 4.5 mm Hg vs. 6.6 ± 8.4 mm Hg; p = 0.70). Forty-sex percent of POAG patients achieved an IOP of <14 mm Hg compared with 17% of secondary glaucoma patients. Among the secondary glaucoma subtypes, netarsudil was found to be most effective for treating uveitic glaucoma, showing a decrease in IOP of 9.5 mm Hg after 12 months (p = 0.02).

Conclusion: Netarsudil is effective in lowering IOP in patients with certain forms of secondary glaucoma and should be considered for IOP management in those with uveitic glaucoma.

Comments:

The study aimed to evaluate the effectiveness of netarsudil, 0.02%, in reducing intraocular pressure (IOP) in patients with secondary forms of glaucoma. The researchers conducted a retrospective review of 77 patients (98 eyes) with primary open-angle glaucoma (POAG) or secondary glaucoma over a one-year period following the initiation of netarsudil treatment. The secondary glaucoma group consisted of patients with various forms of secondary glaucoma, including uveitic, pseudoexfoliative, neovascular, congenital, and others. IOP measurements were taken at baseline and at 1-, 3-, 6-, and 12-month intervals. Statistical analyses, such as two-sample t-tests and one-way analysis of variance, were performed to assess the differences in IOP reductions after netarsudil treatment.

The results showed that both the POAG and secondary glaucoma patients experienced significant decreases in IOP at each time point (1, 3, 6, and 12 months) compared to baseline (p < 0.05). After one year of treatment, both groups exhibited similar overall reductions in IOP from baseline (6.0 ± 4.5 mm Hg vs. 6.6 ± 8.4 mm Hg; p = 0.70). However, a higher percentage of POAG patients (46%) achieved an IOP below 14 mm Hg compared to secondary glaucoma patients (17%). Among the different subtypes of secondary glaucoma, netarsudil was found to be most effective in treating uveitic glaucoma, resulting in a significant IOP reduction of 9.5 mm Hg after 12 months (p = 0.02).

In conclusion, netarsudil demonstrated effectiveness in reducing IOP in patients with certain forms of secondary glaucoma, particularly uveitic glaucoma. The findings suggest that netarsudil should be considered for IOP management in individuals with uveitic glaucoma.